Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease?

References

• Sinclair HM. The diet of Canadian eskimos. Proc. Nutr. Soc. 12, 69–82 (1953).
   Google Scholar
• Bang HO, Dyerber J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am. J. Clin. Nutr. 33, 2657–2661 (1980).
   Google Scholar
• Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic west-coast eskimos. Lancet 1, 1143–1145 (1971).
   Google Scholar
• Bjerregaard P, Dyerberg J. Mortality from ischaemic heart disease and cerebrovascular disease in Greenland. Int. J. Epidemiol. 17, 514–519 (1988).
   Google Scholar
• Newman WP, Middaugh JP, Propst MT, Rogers DR. Atherosclerosis in Alaska natives and non-natives. Lancet 341, 1056–1057 (1993).
   Google Scholar
• Ruxton CHS, Reed SC, Simpson MJA, Millington KJ. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J. Hum. Nutr. Diet. 17, 449–459 (2004).
   Google Scholar
• Sijben JW, Calder PC. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 66, 237–259 (2007).
   Google Scholar
• Grimble RF, Tappia PS. Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids. Z. Ernahrungswiss. 37, 57–65 (1998).
   Google Scholar
• Grimble RF, Tappia PS. Modulatory influence of unsaturated fatty acids on the biology of tumour necrosis factor-alpha. Biochem. Soc. Trans. 23, 282–287 (1995).
   Google Scholar
• Lauritzen L, Hansen HS, Jørgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 40, 1–94 (2001).
   Google Scholar
• Xu YJ, Gregor T, Dhalla NS, Tappia PS. Is the jury still out on the benefits of fish, seal and flax oils in cardiovascular disease. Ann. Nutr. Disord. Ther. 1, 40 (2014).
   Google Scholar
• Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N. Engl. J. Med. 312, 1205–1209 (1985).
   Google Scholar
• Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 2, 757–761 (1989).
   Google Scholar
• Siscovick DS, Raghunathan TE, King I et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J. Am. Med. Assoc. 274, 1363–1367 (1995).
   Google Scholar
• Albert CM, Campos H, Stampfer MJ et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 346, 1113–1118 (2002).
   Google Scholar
• Mozaffarian D, Lemaitre RN, King IB et al. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann. Intern. Med. 158, 515–525 (2013).
   Google Scholar
• Mozaffarian D, Lemaitre RN, King IB et al. Circulating long-chain omega-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann. Intern. Med. 155, 160–170 (2011).
   Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multicenter, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am. J. Cardiol. 108, 682–690 (2011).
   Google Scholar
• Harris WS, Ginsberg HN, Arunakul N et al. Safety and efficacy of omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk 4, 385–391 (1997).
   Google Scholar
• Shaikh NA, Yantha J, Shaikh S et al. Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL Trial. Mol. Cell. Biochem. 396, 9–22 (2014).
   Google Scholar
• GISSI Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell’infarto miocardico. Lancet 354, 447–455 (1999).
   Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded end point analysis. Lancet 369, 1090–1098 (2007).
   Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372, 1223–1230 (2008).
   Google Scholar
• Burr ML, Ashfield WP, Dunstan FDJ et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur. J. Clin. Nutr. 57, 193–200 (2003).
   Google Scholar
• Brouwer IA, Zock PL, Camm AJ et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. J. Am. Med. Assoc. 295, 2613–2619 (2006).
   Google Scholar
• Rauch B, Schiele R, Schneider S et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122, 2152–2159 (2010).
   Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363, 2015–2026 (2010).
   Google Scholar
• Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 112, 298–304 (2002).
   Google Scholar
• Hooper L, Thompson RL, Harrison RA et al. Risks and benefits of omega-3 fats for mortality, cardiovascular disease, and cancer: systematic review. Br. Med. J. 332, 752–760 (2006).
   Google Scholar
• Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin. Cardiol. 32, 365–372 (2009).
   Google Scholar
• Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. J. Am. Med. Assoc. 308, 1024–1033 (2012).
   Google Scholar
• Lewis EJH. Omega-3 fatty acid supplementation and cardiovascular disease events [letter]. J. Am. Med. Assoc. 309, 27 (2013).
   Google Scholar
• Vlachopoulos C, Richter D, Stefanadis C. Omega-3 fatty acid supplementation and cardiovascular disease events. J. Am. Med. Assoc. 309, 28 (2013).
   Google Scholar
• Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 172, 686–694 (2012).
   Google Scholar
• León H, Shibata MC, Sivakumaran S et al. Effect of fish oil on arrhythmias and mortality: systematic review. Br. Med. J. 337, a2931 (2008).
   Google Scholar
• Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br. J. Nutr. 107(Suppl. 2), S201–S213 (2012).
   Google Scholar
• Sekikawa A, Curb JD, Ueshima H et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J. Am. Coll. Cardiol. 52, 417–424 (2008).
   Google Scholar
• Shaikh NA, Downar E, Butany J. Amiodarone – an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol. Cell. Biochem. 76, 163–172 (1987).
   Google Scholar
• Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol. Nutr. Food. Res. 56, 1073–1080 (2012).
   Google Scholar
• Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88, 523–533 (1993).
   Google Scholar
• Cawood AL, Ding R, Napper FL et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212, 252–259 (2010).
   Google Scholar
• Covas MI. Olive oil and the cardiovascular system. Pharmacol. Res. 55, 175–186 (2007).
   Google Scholar
• Estruch R, Ros E. Eat a healthy diet and drink wisely to postpone dying if you survived a myocardial infarction? Yes, but randomized clinical trials are needed. JAMA Intern. Med. 173, 1819–1820 (2013).
   Google Scholar
• Shaikh NA, Shaikh S, Yantha J, Jackowski G. Differential uptake of omega-3 polyunsaturated fatty acids in trial subjects could explain variability of the trials’ outcome. Circulation 130, A20243 (2014).
   Google Scholar
• Pishva H, Mahboob SA, Mehdipour P et al. Fatty acidbinding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects. Nutrition 26, 1117–1121 (2010).
   Google Scholar
• Olano-Martin E, Anil E, Caslake MJ et al. Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 209, 104–110 (2010).
   Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 23, 151–152 (2003).
   Google Scholar